Coeptis Therapeutics Holdings, Inc.: Business Overview, Financials & Competitive Analysis
Coeptis Therapeutics Holdings, Inc. scores 3/10 on the AskCyborg Cyborg Score (Weak). Early-stage cell therapy biotech with diversified pipeline and recent merger creates high-risk, high-reward profile dependent on clinical and regulatory success. Coeptis generated $1.4M in revenue in FY2025 with -$13.0M operating loss and -$11.9M net loss. The company is pre-revenue on its therapeutic pipeline and faces high execution risk.
What is Coeptis Therapeutics Holdings, Inc.'s industry? Coeptis Therapeutics Holdings, Inc. (coeptistx.com) operates in Immunology Drugs. AskCyborg classifies Coeptis Therapeutics Holdings, Inc. under Immunology Drugs in its company registry.
Coeptis Therapeutics is a Wexford, Pennsylvania-based biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. The company compl...
Cyborg Score thesis
Early-stage cell therapy biotech with diversified pipeline and recent merger creates high-risk, high-reward profile dependent on...
Read the full analyst-debate transcript →Get the Latest Coeptis Therapeutics Holdings, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCoeptis Therapeutics Holdings, Inc. Overview
Pro stress-test →Coeptis Therapeutics is a Wexford, Pennsylvania-based biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. The company completed a business combination with Z Squared and listed on the Nasdaq Global Market under ticker ZSQR, effective April 27, 2026.
Strategic Profile
Pro stress-test →Through subsidiaries including Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies, the company focuses on developing cell therapy platforms and related technologies targeting cancer, autoimmune, and infectious diseases. The company operates a technology segment integrating AI-powered solutions to build complementary revenue streams, while maintaining a co-development agreement with Vici Health Sciences for CPT60621, targeting Parkinson's Disease.
Competitive Landscape
Pro stress-test →Coeptis develops cell therapy platforms for cancer treatment. The company competes in the cell therapy and immunotherapy space against established biotech firms and emerging platforms. Competitors include Gilead Sciences (CAR-T therapy), Juno Therapeutics, and numerous other CAR-T and NK cell therapy developers. Competitive advantage derives from SNAP-CAR platform differentiation and multi-indication pipeline breadth.
Industry Context
Coeptis Therapeutics Holdings, Inc. operates in Immunology Drugs.
Key facts
Founded: 2017 · Headquarters: Wexford, Pennsylvania, US · Employees: 105 · Revenue: $1.4M for FY2025 · Market cap: $102.1M (as of April 2026)